Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

3rd China Vaccine Focus 2013

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Events is now in its third time of providing a platform for technology exchange and new business development, new innovation release and is the region’s premier vaccine event in the Asia Pacific.

“China lays out its 12th Five-Year Plan for biopharma industry and the gross output value may reach 3 trillion RMB by 2015 with growth rate of 20% per year. And much importance has been attached to vaccine, mAb, gene engineering and protein engineering, peptides, blood products.”

With the Strong Support from ABO, Bayhelix, KoreaBio, SBIA, and etc, we are targeting towards 300 delegates, 40 exhibitors, and 40 speakers at 3rd China Vaccine Focus 2013 By the present of senior officials from Ministry of Health, PRC, SFDA/ FDA, NICPBP to address the latest regulatory issues on development of China vaccine industry. Through two days’ various sessions such as keynote presentations, interactive panel discussions, case studies, cocktail party and scheduled one-to-one business meetings, you will hear the latest breaking perspectives of both Chinese and MNC vaccine leaders. They will provide insights into their own company strategies for the coming years and how each perceives the marketplace developments. It will help you to win the vaccine market competition and strengthen your company’s dynamic growth in China’s vaccine market.

With nearly 1.4 bn people and approximately 17 million newborns each year, China has already been the largest producer and user of world vaccine products. Enhancing disease prevention awareness in adults, the spread of influenza A/H1N1 and other infectious diseases and Chinese government’s increased investment in epidemic prevention systems, recent improvements in China’s regulation, market, and technology scenario are all together creating an optimistic outlook for its vaccine industry. It is predicted that the vaccine sales revenue of China will increase to 20 billion RMB by 2015 with the growth rate of 10.8%.

CDMC events are devoted to delivering business intelligence by creating opportunities for knowledge sharing and business networking. CDMC endeavors to be the premier platform for acquiring business opportunities and strive to be part of your decision making. We firmly position ourselves as a landmark provider of B to B media service featuring China concept and high acclamation of customer. We pride ourselves in growing with your business and China's economy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!